ArticleMarine biotechnology (New York, N.Y.)2025
Establishment and Characterization of Novel Channa striata Muscle Cell Line for Scaffold-Based Micro-tissue Production.
Article in Marine biotechnology (New York, N.Y.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Channa striata is a hardy fish that can thrive in various aquatic conditions; it is a good source of protein and has high economic value. This study was conducted to establish and characterize the muscle cell line of C. striata and use it to develop micro-tissue using seaweed biofilm. Explant culture was used to create a continuous muscle cell line from C. striata, which was then sub-cultured 143 times in Leibovitz L-15 medium with 10% FBS at 28 °C. They were properly cryopreserved, and after storage, 88-92% of the cells were recovered. The C. striata muscle cell line (CSM) was authenticated by examining the mitochondrial 16S rRNA gene using polymerase chain reaction. The immunophenotyping results revealed that the CSM cells were of myoblast origin, as evidenced by desmin and myosin cell markers. CSM cells showing a myogenic-like phenotype were also demonstrated through lipid droplets, which were confirmed by Nile Red staining. This cell line was devoid of mycoplasma infection. Inducing the foreign gene plasmid pEGFP-N1 resulted in a 16% transfection efficiency. Sterilized biocompatible seaweed biofilm was employed as a scaffold to grow micro-tissue using the developed CSM cell line. After 20 days of growth, this cell line produced micro-tissue on the seaweed biofilm. Seaweed biofilm is a one-of-a-kind biomaterial that has a wide range of biomedical applications, is ecologically friendly, biocompatible, and helps to improve cellular aquaculture and sustainable development.
Indexed as
Identifiers
41065882What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.